Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean aromatase inhibitor?
Displaying drugs 1 - 25 of 2437 in total

Anastrozole

Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such...
Approved
Investigational
Matched Description: … [A186865] Aromatase inhibitors, including anastrozole, have become endocrine drugs of choice in the treatment ... Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating …
Matched Categories: … Aromatase Inhibitors ... Enzyme Inhibitors ... Steroid Synthesis Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors …

Anti-inhibitor coagulant complex

Anti-inhibitor coagulant complex, also known as FEIBA (factor eight inhibitor bypassing activity), contains several proteins involved in the prothrombinase complex. It is used to control bleeding in hemophilia A and B patients with inhibitors.
Approved
Investigational
Matched Description: … It is used to control bleeding in hemophilia A and B patients with inhibitors. …

Estrone

Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione....
Approved
Matched Categories: … BCRP/ABCG2 Inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Organic Anion Transporting Polypeptide 2B1 Inhibitors …

Lacidipine

Lacidipine is a lipophilic dihydropyridine calcium antagonist with an intrinsically slow onset of activity. Due to its long duration of action, lacidipine does not lead to reflex tachycardia . It displays specificity in the vascular smooth muscle, where it acts as an antihypertensive agent to dilate peripheral arterioles and reduce...
Approved
Investigational

Cilostazol

Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Phosphodiesterase Inhibitors ... Phosphodiesterase 3 Inhibitors ... Platelet Aggregation Inhibitors Excl. Heparin …

Velpatasvir

Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common...
Approved
Investigational
Matched Description: … Notably, velpatasvir has a significantly higher barrier to resistance than the first generation NS5A inhibitors …
Matched Categories: … BCRP/ABCG2 Inhibitors ... OATP1B3 inhibitors ... P-glycoprotein inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Organic Anion Transporting Polypeptide 1B1 Inhibitors …

Natalizumab

Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the...
Approved
Investigational

Thrombin alfa

Thrombin Alfa is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line. Thrombin Alfa is identical in amino acid sequence and structurally similar to naturally occurring human thrombin. Thrombin Alfa precursor is secreted to culture medium as single chain form that is proteolytically...
Approved

Ritlecitinib

Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.[L47092,L47127] It was further...
Approved
Investigational
Matched Categories: … Janus Kinase Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors …

Pirtobrutinib

Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK). Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of atrial fibrillation. Unlike BTK covalent inhibitors, such as ibrutinib, that bind to the cysteine 481...
Approved
Investigational
Matched Description: … [A256758] Unlike BTK covalent inhibitors, such as [ibrutinib], that bind to the cysteine 481 (Cys481) ... [A256758,A256773,L44863] However, other mutations may confer resistance to non-covalent BTK inhibitors ... that the presence of Cys481 mutations is the most common reason for resistance to covalent BTK inhibitors …
Matched Categories: … BCRP/ABCG2 Inhibitors ... Enzyme Inhibitors ... P-glycoprotein inhibitors ... Protein Kinase Inhibitors ... Tyrosine Kinase Inhibitors …

Cangrelor

Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion...
Approved
Matched Description: … An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel ... patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors …
Matched Categories: … Platelet Aggregation Inhibitors Excl. Heparin …

Relatlimab

Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3).[A246165,L41265] It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and has garnered interest in the treatment of a variety of cancers, including leukemia and melanoma. As immune checkpoint...
Approved
Investigational
Matched Description: … have been trialed in combination with other checkpoint inhibitors - for example, PD-1 inhibitors like ... [nivolumab] or CTLA-4 inhibitors like [ipilimumab] - to enhance their efficacy. ... [L41305] As immune checkpoint inhibitors have limited efficacy when used alone, drugs like relatlimab …
Matched Categories: … Immune Checkpoint Inhibitors …

Tacrine

A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market.
Approved
Investigational
Withdrawn
Matched Categories: … Enzyme Inhibitors ... Cholinesterase Inhibitors …

Testosterone

Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.[A187114,L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone was isolated from samples and also synthesized in 1935.
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... Thyroxine-binding globulin inhibitors …

Neratinib

Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... P-glycoprotein inhibitors ... Protein Kinase Inhibitors ... Tyrosine Kinase Inhibitors ... Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors …

Andexanet alfa

Andexanet alfa is a recombinant human coagulation Factor Xa that promotes blood coagulation. It was developed by Portola Pharmaceuticals and was approved in in May 2018. It is marketed as Andexxa for intravenous injection or infusion and is indicated for the reversal of anticoagulation in combination with rivaroxaban and apixaban...
Approved
Investigational
Matched Description: … Its pharmacokinetic properties are not reported to be affected by factor Xa inhibitors [A35518]. ... Rivaroxaban and apixaban are Factor Xa inhibitors that promote anticoagulation in situations where blood ... However, the effectiveness of andexanet alfa on treating bleeding related to any FXa inhibitors other …

Tenofovir disoproxil

Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs). This drug is prescribed in combination with other drugs for the management of HIV infection as well as for...
Approved
Investigational
Matched Description: … Viread_, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors …
Matched Categories: … P-glycoprotein inhibitors ... Reverse Transcriptase Inhibitors ... Nucleoside and Nucleotide Reverse Transcriptase Inhibitors …

Asciminib

Asciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein which serves as a driver of CML proliferation in most patients with the disease....
Approved
Investigational
Matched Description: … Existing inhibitors of ABL compete at the ATP binding sites of these proteins and can be classified into …
Matched Categories: … OCT1 inhibitors ... BCRP/ABCG2 Inhibitors ... Enzyme Inhibitors ... UGT1A1 Inhibitors ... OATP1B3 inhibitors …

Omeprazole

Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class,...
Approved
Investigational
Vet approved
Matched Categories: … BCRP/ABCG2 Inhibitors ... Enzyme Inhibitors ... Proton Pump Inhibitors ... Proton-pump Inhibitors ... P-glycoprotein inhibitors …

Spirapril

Spirapril is an ACE inhibitor antihypertensive drug used to treat hypertension. Spirapril is converted to the active spiraprilat after administration. ACE inhibitors are used primarily in treatment of hypertension and congestive heart failure.
Approved
Matched Description: … ACE inhibitors are used primarily in treatment of hypertension and congestive heart failure. …
Matched Categories: … Enzyme Inhibitors ... Protease Inhibitors ... Angiotensin-Converting Enzyme Inhibitors …

Avanafil

Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both sildenafil and vardenafil but less selectivity than tadalafil, suggesting a relatively lower risk of visual disturbances associated with...
Approved
Matched Categories: … BCRP/ABCG2 Inhibitors ... Phosphodiesterase Inhibitors ... Phosphodiesterase 5 Inhibitors …

Mivacurium

Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission.
Approved

Betrixaban

Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Factor Xa Inhibitors ... Protease Inhibitors ... Direct factor Xa inhibitors ... Serine Protease Inhibitors …

Atracurium besylate

A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.
Approved

Metocurine iodide

Metocurine iodide is a benzylisoquinolinium competitive nondepolarizing neuromuscular blocking agent. It is used as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy Metocurine iodide has a moderate risk of inducing histamine release and has some ganglion blocking activity. Metocurine...
Approved
Withdrawn
Displaying drugs 1 - 25 of 2437 in total